Trending news
Analyze
Pricing
Sequenta

Sequenta

Work at Sequenta? Add yourself to this profile

Sequenta

is dedicated to improving patient care in diseases mediated by immune cells. Our ClonoSIGHT™ test for MRD in lymphoid cancers launched in 2013.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Venture capital
Venture capital (Series C)
$20,000,000
Foresite Capital
Locations
Venture capital
businesswire

Celgene Participates in New Round of Investment for Sequenta